Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
Preoperative letrozole versus letrozole with metformin in postmenopausal Estrogen receptor
positive breast cancer patients
Phase II multicenter 1:1 randomized clinical trial Total 208 patients
Primary endpoint Clinical response rate
Secondary endpoint Pathologic complete response rate Breast conserving surgery rate Percent
mammographic density change Ki67(%) change after 4week medication of 2nd core needle biopsy
Toxicity profile of neoadjuvant letrozole, metformin